BioNTech SE (NASDAQ:BNTX) trading with an addition of $1.86 to $251.26 on Thursday, an upside of 0.75 percent. An average of 1,288,554 shares of common stock have been traded in the last five days. There was a gain of $4.73 in the past week, and it reached a new high 37 times over the past 12 months. The last 20 days have seen an average of 2,889,749 shares traded, while the 50-day average volume stands at 4,109,491.
BNTX stock has decreased by -25.53% in the last month. The company shares reached their 1-month lowest point of $230.03 on 10/01/21. With the stock rallying to its 52-week high on 08/10/21, shares of the company touched a low of $75.35 and a high of $464.00 in 52 weeks. It has reached a new high 42 times so far this year and achieved 205.94% or $169.78 in price. In spite of this, the price is down -45.85% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
BioNTech SE (BNTX) has a trailing price-to-earnings (P/E) ratio of 13.21, which compares with the 34.65 for the broader industry and 32.77 for the sector. In the last five years, BioNTech SE’s PE ratio has ranged between 749.25 and 10.77. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.76, the price-to-book (PB) ratio at 9.61.
The quick ratio of BioNTech SE for the three months ended June 29 was 2.60, and the current ratio was 2.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.09 and a total debt to equity ratio of 0.22 for the quarter ending June 29. BioNTech SE’s EBITDA margin for the year ending June 29 is -47.24%, while its operating margin for the same period stands at 76.20%. Its gross profit as reported stood at $483.18 million compared to revenue of $550.96 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, BioNTech SE’s return on assets was 95.10%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, BioNTech SE had $1.01 million in cash and short-term investments compared to $0.63 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $17.02 million in the quarter, while revenues were grew 1278.26%. The analyst consensus anticipated BioNTech SE’s latest quarter earnings to come in at $8.77 per share, but it turned out to be $12.46, a 42.10% surprise. For the quarter, EBITDA amounted to $5.08 billion.
From a technical analysis perspective, let’s take a brief look at BioNTech SE (BNTX) price momentum. RSI 9-day as of the close on 13 October was 34.73%, suggesting the stock is Neutral, with historical volatility in this time frame at 42.53%.
As of today, BNTX’s price is $246.69 +1.92% or $4.73 from its 5-day moving average. BNTX is currently trading -32.56% lower than its 20-day SMA and +28.94% higher than its 100-day SMA. However, the stock’s current price level is -39.36% below the SMA50 and +184.66% above the SMA200.
The stochastic %K and %D were 15.40% and 12.85%, respectively, and the average true range (ATR) was 15.95. With the 14-day stochastic at 19.61% and the average true range at 18.21, the RSI (14) stands at 36.00%. The stock has reached 2.03 on the 9-day MACD Oscillator while the 14-day reading was at -9.27.
Jefferies launched coverage on BioNTech SE (NASDAQ: BNTX) in its analyst report released on October 07, 2021. The firm assigned the stock a a Hold rating.The consensus rating for BioNTech SE (BNTX) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell BNTX, while 8 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is BNTX’s price target for the next 12 months?
Analysts predict a range of price targets between $130.36 and $384.66, with a median target of $311.97. Taking a look at these predictions, the average price target given by analysts for BioNTech SE (BNTX) stock is $287.09.